301 related articles for article (PubMed ID: 33042651)
1. Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors: Benefits in Diabetics With Cardiovascular Disease.
Aftab S; Vetrivel Suresh R; Sherali N; Daniyal M; Tsouklidis N
Cureus; 2020 Oct; 12(10):e10783. PubMed ID: 33042651
[TBL] [Abstract][Full Text] [Related]
2. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors.
Scheen AJ
Circ Res; 2018 May; 122(10):1439-1459. PubMed ID: 29748368
[TBL] [Abstract][Full Text] [Related]
3. The role of sodium glucose cotransporter-2 (SGLT-2) inhibitors in heart failure and chronic kidney disease in type 2 diabetes.
Woo V; Connelly K; Lin P; McFarlane P
Curr Med Res Opin; 2019 Jul; 35(7):1283-1295. PubMed ID: 30767677
[No Abstract] [Full Text] [Related]
4. The Cardiovascular Benefits Associated with the Use of Sodium-Glucose Cotransporter 2 Inhibitors - Real-World Data.
Gallwitz B
Eur Endocrinol; 2018 Apr; 14(1):17-23. PubMed ID: 29922347
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of sodium glucose cotransporter-2 inhibitors in the management of type 2 diabetes mellitus: A real-world experience.
Islam L; Jose D; Alkhalifah M; Blaibel D; Chandrabalan V; Pappachan JM
World J Diabetes; 2024 Mar; 15(3):463-474. PubMed ID: 38591092
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Benefit of Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Type 2 Diabetes: A Systematic Review.
Georgiou P; Shi W; Serhiyenia T; Akram A; Proute MC; Pradeep R; Kerolos ME; Khan S
Cureus; 2021 Oct; 13(10):e18485. PubMed ID: 34754647
[TBL] [Abstract][Full Text] [Related]
7. Cardio-renal protection with empagliflozin.
MacIsaac RJ; Jerums G; Ekinci EI
Ann Transl Med; 2016 Oct; 4(20):409. PubMed ID: 27867961
[TBL] [Abstract][Full Text] [Related]
8. [Outcome studies on SGLT-2 inhibitors].
Seufert J; Laubner K
Internist (Berl); 2019 Sep; 60(9):903-911. PubMed ID: 31375850
[TBL] [Abstract][Full Text] [Related]
9. Implications and Economic Impact of Applying International Guidelines and Recommendations to the Management of High-Risk Group of Type 2 Diabetes Mellitus Patients in India.
Fatima Z; Atal S; Joshi R; Sadasivam B
Cureus; 2022 Feb; 14(2):e22141. PubMed ID: 35308676
[TBL] [Abstract][Full Text] [Related]
10. The Pleiotropic Effects of Sodium-Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit.
Patel DK; Strong J
Diabetes Ther; 2019 Oct; 10(5):1771-1792. PubMed ID: 31456166
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of sodium glucose cotransporter 2 inhibitors.
Cavaiola TS; Pettus J
Diabetes Metab Syndr Obes; 2018; 11():133-148. PubMed ID: 29695924
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular Effects of Sodium Glucose Co-transporter-2 Inhibitors in Patients with Type 2 Diabetes Mellitus.
Kumar S; Talwalkar PG; Das S; Goswami S
Indian J Endocrinol Metab; 2019; 23(1):150-158. PubMed ID: 31016170
[TBL] [Abstract][Full Text] [Related]
13. Effects of sodium-glucose cotransporter 2 inhibitors on serum uric acid in patients with type 2 diabetes mellitus: A systematic review and network meta-analysis.
Hu X; Yang Y; Hu X; Jia X; Liu H; Wei M; Lyu Z
Diabetes Obes Metab; 2022 Feb; 24(2):228-238. PubMed ID: 34617381
[TBL] [Abstract][Full Text] [Related]
14. Renal effects of sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes and renal impairment.
Weir MR
Postgrad Med; 2019 Aug; 131(6):367-375. PubMed ID: 31132013
[TBL] [Abstract][Full Text] [Related]
15. Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus.
Rehman SU; Rahman F
Cureus; 2020 Aug; 12(8):e9655. PubMed ID: 32802621
[TBL] [Abstract][Full Text] [Related]
16. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
Heerspink HJ; Perkins BA; Fitchett DH; Husain M; Cherney DZ
Circulation; 2016 Sep; 134(10):752-72. PubMed ID: 27470878
[TBL] [Abstract][Full Text] [Related]
17. Sodium-glucose cotransporter 2 inhibitors: an evidence-based practice approach to their use in the natural history of type 2 diabetes.
Schwartz SS; Ahmed I
Curr Med Res Opin; 2016 May; 32(5):907-19. PubMed ID: 26854518
[TBL] [Abstract][Full Text] [Related]
18. Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.
Cruz JE; Ahuja T; Bridgeman MB
Ann Pharmacother; 2018 Dec; 52(12):1238-1249. PubMed ID: 29911393
[TBL] [Abstract][Full Text] [Related]
19. Adverse events associated with sodium glucose co-transporter 2 inhibitors: an overview of quantitative systematic reviews.
Pelletier R; Ng K; Alkabbani W; Labib Y; Mourad N; Gamble JM
Ther Adv Drug Saf; 2021; 12():2042098621989134. PubMed ID: 33552467
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular outcomes with sodium-glucose cotransporter-2 inhibitors in patients with type II diabetes mellitus: A meta-analysis of placebo-controlled randomized trials.
Saad M; Mahmoud AN; Elgendy IY; Abuzaid A; Barakat AF; Elgendy AY; Al-Ani M; Mentias A; Nairooz R; Bavry AA; Mukherjee D
Int J Cardiol; 2017 Feb; 228():352-358. PubMed ID: 27866027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
